SCHEMBL21451040

SCHEMBL21451040

CN(C)c1ccc2sc3c(Cl)nc4ccccc4c3c(=O)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 1/20 0.41
TOP2A P11388 1/20 0.41
KDM4E B2RXH2 4/20 0.40
LMNA P02545 2/20 0.40
HPGD P15428 2/20 0.40
RAB9A P51151 4/20 0.38
MAPT P10636 3/20 0.38
NPC1 O15118 3/20 0.38
GUSB P08236 1/20 0.38
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
KDM1A O60341 4/20 0.37
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPK1 P28482 1/20 0.36
SLC2A1 P11166 1/20 0.36
TP53 P04637 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
APP P05067 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21450975 0.84 ALDH1A1 (0.46) TOP1TOP2AKDM4ELMNAHPGD
SCHEMBL17655673 0.84 KDM4E (0.58) TOP1TOP2AKDM4ELMNAHPGD
SCHEMBL21450906 0.82 TOP1 (0.43) TOP1TOP2AKDM4EHPGDRAB9A
SCHEMBL21450818 0.81 KDM4E (0.59) TOP1TOP2AKDM4ELMNAHPGD
SCHEMBL16338804 0.79 KDM4E (0.49) TOP1TOP2AKDM4ELMNAMAPT
SCHEMBL21451018 0.79 TOP1 (0.41) TOP1TOP2AKDM4EMAPTTP53
SCHEMBL30163600 0.79 KDM4E (0.49) TOP1TOP2AKDM4ELMNAMAPT
SCHEMBL21450985 0.79 TOP1 (0.44) TOP1TOP2AKDM4EHPGDRAB9A
SCHEMBL21451080 0.79 NPC1 (0.43) TOP1TOP2AKDM4ELMNAHPGD
SCHEMBL21451124 0.79 MAPT (0.43) TOP1TOP2AKDM4ELMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332476-B2 Fms-like tyrosine kinase inhibitors 3SM BIOTRON INC. (TW) 2022-05-17 US disclosed
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS Sagabio Co., Ltd. (TW) 2020-04-30 US disclosed
WO-2019191896-A1 FMS-LIKE TYROSINE KINASE INHIBITORS 3SM BIOTRON INC. (CN) 2019-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332476-B2 Fms-like tyrosine kinase inhibitors FLT3, FLT4, FLT1 TOP1 2980/4885TOP2A 2701/4885KDM4E 1341/4885
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS FLT3, FLT4, FLT1 TOP1 2980/4885TOP2A 2701/4885KDM4E 1341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.